Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of pemetrexed (Alimta) combined with paclitaxel in recurrent/advanced follicular, papillary or anaplastic thyroid cancer
2008-001032-12Phase 2Withdrawn
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and paclitaxel in follicular carcinoma (FTC) and papillary thyroid cancer (PTC), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Objective response rate. Planned start Jul 2008; status: withdrawn.
02
Drugs
pemetrexedpaclitaxel
03
Conditions
follicular carcinoma (FTC)papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on 2008-001032-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001032-12.